214470-55-0 Usage
Description
4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE is an organic compound characterized by its quinoline core structure, featuring a chloro group at the 4th position, two methoxy groups at the 6th and 7th positions, and a carbonitrile group at the 3rd position. 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE is known for its potential applications in the pharmaceutical and chemical industries due to its unique structural properties.
Uses
Used in Pharmaceutical Industry:
4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE is used as a reactant in the synthesis of Src kinase activity inhibitors. Src kinases are non-receptor tyrosine kinases that play a crucial role in various cellular processes, including cell proliferation, survival, and migration. Inhibition of Src kinase activity has been shown to have therapeutic potential in the treatment of various diseases, such as cancer and inflammatory disorders.
As a reactant in the synthesis of Src kinase inhibitors, 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE contributes to the development of novel therapeutic agents that can modulate the activity of these kinases, thereby providing potential treatment options for patients suffering from diseases associated with abnormal Src kinase activity.
Additionally, due to its unique structural features, 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE may also find applications in other areas of the pharmaceutical industry, such as the development of new drugs targeting different biological pathways or as a building block for the synthesis of other bioactive compounds.
Used in Chemical Industry:
In the chemical industry, 4-CHLORO-6,7-DIMETHOXY-QUINOLINE-3-CARBONITRILE may be utilized as an intermediate in the synthesis of various organic compounds, including those with potential applications in materials science, agrochemicals, and other specialty chemicals. Its unique structural features make it a valuable building block for the development of new molecules with specific properties and functions.
Furthermore, the compound's reactivity and functional groups can be exploited in various chemical reactions, such as substitution, addition, and condensation reactions, to produce a wide range of derivatives with diverse applications in the chemical industry.
Synthesis Reference(s)
Journal of Medicinal Chemistry, 43, p. 3244, 2000 DOI: 10.1021/jm000206a
Check Digit Verification of cas no
The CAS Registry Mumber 214470-55-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,4,4,7 and 0 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 214470-55:
(8*2)+(7*1)+(6*4)+(5*4)+(4*7)+(3*0)+(2*5)+(1*5)=110
110 % 10 = 0
So 214470-55-0 is a valid CAS Registry Number.
InChI:InChI=1/C12H9ClN2O2/c1-16-10-3-8-9(4-11(10)17-2)15-6-7(5-14)12(8)13/h3-4,6H,1-2H3
214470-55-0Relevant articles and documents
PHOSPHODIESTERASE INHIBITORS AND USE
-
Paragraph 0112; 0114, (2021/04/02)
The invention provides compounds that may inhibits to ENPP1, and are accordingly useful for treatment disorders related to ENPP1. The invention further provides pharmaceutical compositions containing these compounds and methods of using these compounds to treat or prevent disorders related to ENPP1.
3-AMINOTHIENO[3,2-c]QUINOLINE DERIVATIVES, METHODS OF PREPARATION AND USES
-
, (2013/10/08)
The present invention relates to compounds according to Formula I: and salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, X, and Y are as defined herein. Methods for preparing co
Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors
Pannala, Madhavi,Kher, Sunil,Wilson, Norma,Gaudette, John,Sircar, Ila,Zhang, Shao-Hui,Bakhirev, Alexei,Yang, Guang,Yuen, Phoebe,Gorcsan, Frank,Sakurai, Naoki,Barbosa, Miguel,Cheng, Jie-Fei
, p. 5978 - 5982 (2008/03/11)
Synthesis and structure-activity relationship of a series of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitrile derivatives as EGFR inhibitors is described. Compounds 29 and 30 showed potent in vitro inhibitory activity in the enzymatic assay as well as in the functional cellular assay. They are moderately selective against other types of tyrosine kinases.
